Cargando…

Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial

RATIONALE & OBJECTIVE: In kidney transplant recipients (KTRs), a belatacept-based immunosuppressive regimen is associated with beneficial effects on cardiovascular (CV) risk factors compared with calcineurin inhibitor (CNI)–based regimens. Our objective was to compare the calculated CV risk betw...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bredewold, Obbo W., Chan, Joe, Svensson, My, Bruchfeld, Annette, de Fijter, Johan W., Furuland, Hans, Grinyo, Josep M., Hartmann, Anders, Holdaas, Hallvard, Hellberg, Olof, Jardine, Alan, Mjörnstedt, Lars, Skov, Karin, Smerud, Knut T., Soveri, Inga, Sørensen, Søren S., Zonneveld, Anton-Jan van, Fellström, Bengt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803830/ https://www.ncbi.nlm.nih.gov/pubmed/36593877 http://dx.doi.org/10.1016/j.xkme.2022.100574

Ejemplares similares

A case of mononucleosis infectiosa presenting with cholemic nephrosis
por: Bredewold, Obbo W., et al.
Publicado: (2011)

Effect of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study
por: Fellström, Bengt, et al.
Publicado: (2005)

Belatacept As an Alternative to Calcineurin Inhibitors in Patients with Solid Organ Transplants
por: Kumar, Dhiren, et al.
Publicado: (2017)

Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients – a pilot study
por: Bremer, Sara, et al.
Publicado: (2009)

Early calcineurin-inhibitor to belatacept conversion in steroid-free kidney transplant recipients
por: Tawhari, Ibrahim, et al.
Publicado: (2022)

Neopterin is associated with cardiovascular events and all-cause mortality in renal transplant patients
por: Pihlstrøm, Hege, et al.
Publicado: (2014)

Symmetric Dimethylarginine as Predictor of Graft loss and All-Cause Mortality in Renal Transplant Recipients
por: Pihlstrøm, Hege, et al.
Publicado: (2014)

Arteriovenous fistula thrombosis is associated with increased all-cause and cardiovascular mortality in haemodialysis patients from the AURORA trial
por: Girerd, Sophie, et al.
Publicado: (2019)

Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score
por: Ussif, Amin, et al.
Publicado: (2018)

Preservation of Antiviral Immunologic Efficacy Without Alloimmunity After Switch to Belatacept in Calcineurin Inhibitor–Intolerant Patients
por: Schaenman, Joanna, et al.
Publicado: (2022)

Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor–free, Belatacept Plus Everolimus–based Immunosuppression
por: Peddi, V. Ram, et al.
Publicado: (2023)

Day-to-day variation of the kidney proximal tubular injury markers urinary cystatin C, KIM1, and NGAL in patients with chronic kidney disease
por: Soveri, Inga, et al.
Publicado: (2020)

Late Conversion From Calcineurin Inhibitors to Belatacept in Kidney-Transplant Recipients Has a Significant Beneficial Impact on Glycemic Parameters
por: Terrec, Florian, et al.
Publicado: (2019)

Three-Year Outcomes in Kidney Transplant Recipients Switched From Calcineurin Inhibitor-Based Regimens to Belatacept as a Rescue Therapy
por: Morel, Antoine, et al.
Publicado: (2022)

Assessment of Renal Transplant Perfusion by Contrast-Enhanced Ultrasound after Switch from Calcineurin Inhibitor to Belatacept: A Pilot Study
por: Osmanodja, Bilgin, et al.
Publicado: (2022)

Effects of spironolactone on extrasystoles and heart rate variability in haemodialysis patients: a randomised crossover trial
por: Eklund, Michael, et al.
Publicado: (2021)

Improved cardiovascular risk prediction in patients with end-stage renal disease on hemodialysis using machine learning modeling and circulating microribonucleic acids
por: de Gonzalo-Calvo, David, et al.
Publicado: (2020)

Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept
por: Choi, Mira, et al.
Publicado: (2020)

Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients: the AURORA trial
por: Salib, Madonna, et al.
Publicado: (2021)

Belatacept: Good, but not good enough?
por: Parameswaran, Sreejith, et al.
Publicado: (2012)

Belatacept: the challenges with transformational drugs
por: Vincenti, Flavio
Publicado: (2017)

Effect of spironolactone on vascular stiffness in hemodialysis patients: a randomized crossover trial
por: Eklund, Michael, et al.
Publicado: (2022)

Acute effects of haemodialysis on circulating microparticles
por: de Laval, Philip, et al.
Publicado: (2018)

Belatacept: A worthy alternative to cyclosporine?
por: Melvin, George, et al.
Publicado: (2012)

Belatacept for Maintenance Immunosuppression in Lung Transplantation
por: Hui, Christine, et al.
Publicado: (2014)

Belatacept in renal transplantation—quo vadis?
por: Westhoff, Timm H.
Publicado: (2016)

Novel Biomarkers Detected by Proteomics Predict Death and Cardiovascular Events in Hemodialysis Patients
por: Wu, Ping-Hsun, et al.
Publicado: (2022)

Ten‐year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4‐weekly or 8‐weekly
por: Vincenti, F., et al.
Publicado: (2017)

Early Conversion from Tacrolimus to Belatacept in a Highly Sensitized Renal Allograft Recipient with Calcineurin Inhibitor-Induced de novo Post-Transplant Hemolytic Uremic Syndrome
por: Tatapudi, Vasishta S., et al.
Publicado: (2018)

Belatacept Conversion in Kidney After Liver Transplantation
por: Cristea, Octav, et al.
Publicado: (2021)

A case of belatacept-induced chilblain lupus
por: Kinariwalla, Neha, et al.
Publicado: (2022)

NT-proBNP and stem cell factor plasma concentrations are independently associated with cardiovascular outcomes in end-stage renal disease hemodialysis patients
por: Rossignol, P, et al.
Publicado: (2022)

Alloreactive CD154-expressing T-cell subsets with differential sensitivity to the immunosuppressant, belatacept: potential targets of novel belatacept-based regimens
por: Ashokkumar, Chethan, et al.
Publicado: (2015)

CD28 Family and Chronic Rejection: “To Belatacept...and Beyond!”
por: Silva, Marcos V., et al.
Publicado: (2012)

Belatacept and mediastinal histoplasmosis in a kidney transplant patient
por: Trimarchi, Hernán, et al.
Publicado: (2016)

Belatacept in kidney transplant patients with systemic lupus erythematosus
por: Carrión-Barberà, Irene, et al.
Publicado: (2019)

Time-Limited Therapy with Belatacept in Kidney Transplant Recipients
por: Letellier, Thibault, et al.
Publicado: (2022)

Albumin Urinary Excretion Is Associated with Increased Levels of Urinary Chemokines, Cytokines, and Growth Factors Levels in Humans
por: Fellström, Bengt, et al.
Publicado: (2021)

Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update
por: Holdaas, Hallvard, et al.
Publicado: (2016)

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients
por: Shen, Jinshan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_es2cp0l2d4vs1kudaj7j6qpqi0